

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant: Yuping Xia, et al.**

**Serial No.: to be assigned**

**Div. of USSN 09/773,877**

**Group: to be assigned**

**Filing Date: Concurrently herewith**

**Examiner: to be assigned**

**Title: METHODS OF TREATING INFLAMMATORY SKIN DISEASES**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
US Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

**REQUEST FOR TRANSFER OF REFERENCE COPIES**

[X] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/773,877, filed January 31, 2001, be transferred to the subject application for consideration by the Examiner

**Fees**

No fee deemed necessary. However, if any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted

  
\_\_\_\_\_

Valeta Gregg

Reg. No. 35,127

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.: : REG 710E

USSN : to be assigned  
Div. of USSN: 09/773,877

Applicant : Yuping Xia, et al.

Date Filed : Concurrently herewith

For : METHODS OF TREATING  
INFLAMMATORY SKIN DISEASES

Examiner : TO BE ASSIGNED

Group Art Unit : TO BE ASSIGNED

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	<u>6,011,003</u>	<u>1/4/00</u>	<u>Charnock-Jones, et al.</u>	_____	_____
_____	<u>5,712,380</u>	<u>1/27/98</u>	<u>Kendall, et al.</u>	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u>	
					<u>Yes</u>	<u>No</u>
_____	<u>WO98/13071</u>	<u>4/2/98</u>	<u>PCT</u>	_____	_____	_____
_____	<u>WO97/44453</u>	<u>11/27/97</u>	<u>PCT</u>	_____	_____	_____

## OTHER DOCUMENTS

**Examiner**  
**Initials**

- \_\_\_\_\_ DeVries, C., et al., 1992, Science, "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," 255:989-91.
- \_\_\_\_\_ Sharifi, J., et al., 1998, The Quarterly Journ of Nucl Med, "Improving monoclonal antibody pharmacokinetics via chemical modification," 42:242-49.
- \_\_\_\_\_ Jensen-Pippo, K. E., et al., 1996, Pharm Research, "Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(ethylene glycol)," 13:102-7.
- \_\_\_\_\_ Tanaka, K., et al., 1997, Jpn J Cancer Res, "Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptror-1 (Flt-1 Tyrosine Kinase)," 88:867-76.
- \_\_\_\_\_ Tiilikainen, A., et al., 1980, Brit J of Dermatology, "Psoriasis and HLA-Cw6," 102:179-184.
- \_\_\_\_\_ Nickoloff B.J., 1999, Arch Dermatol, "The Immunologic and Genetic Basis of Psoriasis," 135:1104-10.
- \_\_\_\_\_ Altman, E., et al., 1999, Sem in Cutaneous Med and Surg, "Diagnosis: Psoriasis or Not? What are the Clues?" 18:25-35.

\_\_\_\_ Detmar, M., et al., 1994, Journal of Exp Med, "Overexpression of Vascular Permeability Factor/vascular Endothelial Growth Factor and its Receptors in Psoriasis," 180:1141-6.

\_\_\_\_ Detmar, M., et al., 1998, Journal of Invest Dermatol, "Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice," 111(1):1-6.

\_\_\_\_ Brown, L.F., et al., 1995, Journal of Invest Dermatol, "Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme," 104(5):744-9.

\_\_\_\_ Suri, C., et al., 1998, Science, "Increased Vascularization in Mice Overexpressing Angiopoietin-1," 282:468-71.

\_\_\_\_ DeLisser, H.M., et al., 1994, Immunol Today, "Molecular and functional aspects of PECAM-1/CD31," 15(10):490-5.

\_\_\_\_ Wrone-Smith, T., and Nickoloff, B.J., 1996, J Clin Invest, "Dermal Injection of Immunocytes Induces Psoriasis," 98(8):1878-87.

\_\_\_\_ Nickoloff, B.J., and Wrone-Smith, T., 1999, Am J of Pathol, "Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis," 155(1):145-58.

\_\_\_\_ Hunt, T.K., 1980, World J Surg., "Disorders of Wound Healing," 4:271-77.

\_\_\_\_\_ Dvorak, H.F., et al., 1995, Am J Pathol, "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis," 146(5):1029-39.

\_\_\_\_\_ Brown, L.F., et al., 1992, J Exp Med, "Expression of Vascular Permeability (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes during Wound Healing," 176(5):1375-9.


EXAMINER  
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

  
Valeta Gregg  
Reg. No. 35,127  
Attorney for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400